Anti-PD-1/PD-L1 monoclonal antibodies end in a novel spectrum of uncomfortable side effects, extensively referred to as immune-related hostile occasions. Toripalimab is an anti-PD-1 monoclonal antibody used for the therapy of some cancers. Right here we report the primary case, to our data, of oral lichenoid drug response triggered by toripalimab. A 78-year-old man who was […]
